Published in Am J Physiol Endocrinol Metab on February 22, 2005
The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol (2011) 2.02
The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance. Endocr Rev (2009) 1.57
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Bioactives of Artemisia dracunculus L enhance cellular insulin signaling in primary human skeletal muscle culture. Metabolism (2008) 1.27
Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol (2013) 1.17
Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep (2013) 1.01
Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice. Circ Heart Fail (2013) 0.99
Endogenously produced adiponectin protects cardiomyocytes from hypertrophy by a PPARgamma-dependent autocrine mechanism. Am J Physiol Heart Circ Physiol (2010) 0.90
Proteomic analysis reveals cellular pathways regulating carbohydrate metabolism that are modulated in primary human skeletal muscle culture due to treatment with bioactives from Artemisia dracunculus L. J Proteomics (2012) 0.85
Molecular determinants of the cardiometabolic phenotype. Endocr Metab Immune Disord Drug Targets (2010) 0.84
Endogenous peroxisome proliferator-activated receptor-gamma augments fatty acid uptake in oxidative muscle. Endocrinology (2008) 0.83
In vivo postprandial lipid partitioning in liver and skeletal muscle in prediabetic and diabetic rats. Diabetologia (2012) 0.80
Effect of serum replacement with plysate on cell growth and metabolismin primary cultures of human skeletal muscle. Cytotechnology (2005) 0.79
Lipid Use and Misuse by the Heart. Circ Res (2016) 0.79
Multi-tissue computational modeling analyzes pathophysiology of type 2 diabetes in MKR mice. PLoS One (2014) 0.78
Ergosterol Alleviates Kidney Injury in Streptozotocin-Induced Diabetic Mice. Evid Based Complement Alternat Med (2015) 0.78
Altered Myokine Secretion Is an Intrinsic Property of Skeletal Muscle in Type 2 Diabetes. PLoS One (2016) 0.76
Recombinant human growth hormone and insulin-like growth factor-1 do not affect mitochondrial derived highly reactive oxygen species production in peripheral blood mononuclear cells under conditions of substrate saturation in-vitro. Nutr Metab (Lond) (2016) 0.75
ShRNA-mediated gene silencing of lipoprotein lipase improves insulin sensitivity in L6 skeletal muscle cells. Biochem Biophys Res Commun (2015) 0.75
Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases? Int J Mol Sci (2016) 0.75
The effect of exercise training combined with PPARγ agonist on skeletal muscle glucose uptake and insulin sensitivity in induced diabetic obese Zucker rats. J Exerc Nutrition Biochem (2016) 0.75
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med (2006) 9.53
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care (2007) 6.24
Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med (2011) 4.28
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
Adiponectin: more than just another fat cell hormone? Diabetes Care (2003) 3.30
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2016 EXECUTIVE SUMMARY. Endocr Pract (2016) 3.01
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology (2013) 2.70
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care (2013) 2.17
Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther (2008) 1.95
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 1.85
Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care (2003) 1.85
Adiponectin in health and disease. Diabetes Obes Metab (2007) 1.64
Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril (2007) 1.63
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reduction. Diabetes (2003) 1.62
Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract (2004) 1.55
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther (2012) 1.51
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A (2013) 1.45
Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes (2002) 1.44
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance. J Clin Invest (2011) 1.33
Thiazolidinedione safety. Expert Opin Drug Saf (2012) 1.33
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab (2013) 1.30
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract (2003) 1.26
Changes in ghrelin and ghrelin receptor expression according to feeding status. Neuroreport (2003) 1.24
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes (2003) 1.23
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2012) 1.22
Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. J Am Diet Assoc (2003) 1.22
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther (2013) 1.17
Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab (2007) 1.17
Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord (2009) 1.15
Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes (2002) 1.15
Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J Clin Endocrinol Metab (2008) 1.13
Electron paramagnetic spectroscopic evidence of exercise-induced free radical accumulation in human skeletal muscle. Free Radic Res (2007) 1.08
Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci (2011) 1.08
Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes (2002) 1.06
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med (2010) 1.06
Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity. Obes Res (2005) 1.04
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care (2002) 1.03
Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care (2003) 1.03
The clinical approach to the detection of lipodystrophy - an AACE consensus statement. Endocr Pract (2013) 1.02
Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care (2013) 1.01
Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue. Am J Physiol Endocrinol Metab (2008) 1.01
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. Adipocyte (2013) 1.01
Sedentary aging increases resting and exercise-induced intramuscular free radical formation. J Appl Physiol (1985) (2010) 0.99
Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev (2006) 0.98
Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol (2004) 0.98
Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep (2002) 0.98
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes (2013) 0.97
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab (2006) 0.97
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract (2016) 0.97
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphism. J Clin Endocrinol Metab (2005) 0.95
In vivo activation of ROCK1 by insulin is impaired in skeletal muscle of humans with type 2 diabetes. Am J Physiol Endocrinol Metab (2010) 0.95
Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab (2003) 0.94
Incretin therapies: effects beyond glycemic control. Am J Med (2009) 0.93
Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin or adiponectin multimeric complexes. Am J Physiol Regul Integr Comp Physiol (2006) 0.93
Role of myotonic dystrophy protein kinase (DMPK) in glucose homeostasis and muscle insulin action. PLoS One (2007) 0.92
Regulation of skeletal muscle morphology in type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal. Metabolism (2003) 0.92
Nonreceptor tyrosine phosphatase Shp2 promotes adipogenesis through inhibition of p38 MAP kinase. Proc Natl Acad Sci U S A (2012) 0.91
Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. Am J Physiol Endocrinol Metab (2009) 0.90
Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. J Clin Endocrinol Metab (2008) 0.89
Enhanced insulin signaling via Shc in human breast cancer. Metabolism (2003) 0.89
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care (2012) 0.88
Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles. Diabetes Care (2002) 0.88
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab (2003) 0.88
Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. Curr Atheroscler Rep (2008) 0.87
Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol Metab Clin North Am (2004) 0.86
Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cells. Endocrinology (2007) 0.86
Dose-specific or dose-dependent effect of growth hormone treatment on the proliferation and differentiation of cultured neuronal cells. Growth Horm IGF Res (2007) 0.86
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. Endocr Pract (2015) 0.85
Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance. Am J Physiol Endocrinol Metab (2014) 0.85
Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab (2004) 0.85
Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation. J Nutr Biochem (2013) 0.83